Tudor Investment Corp ET AL Sells 320,361 Shares of NeoGenomics, Inc. $NEO

Tudor Investment Corp ET AL cut its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 46.0% during the 3rd quarter, Holdings Channel.com reports. The firm owned 375,351 shares of the medical research company’s stock after selling 320,361 shares during the quarter. Tudor Investment Corp ET AL’s holdings in NeoGenomics were worth $2,898,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Royal Bank of Canada increased its stake in shares of NeoGenomics by 51.2% in the first quarter. Royal Bank of Canada now owns 56,026 shares of the medical research company’s stock worth $532,000 after purchasing an additional 18,966 shares in the last quarter. AQR Capital Management LLC bought a new stake in shares of NeoGenomics in the first quarter valued at approximately $271,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of NeoGenomics by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 75,798 shares of the medical research company’s stock valued at $719,000 after purchasing an additional 3,254 shares during the period. Intech Investment Management LLC lifted its stake in shares of NeoGenomics by 19.7% during the 1st quarter. Intech Investment Management LLC now owns 151,806 shares of the medical research company’s stock valued at $1,441,000 after buying an additional 24,965 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in shares of NeoGenomics by 256.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 15,530 shares of the medical research company’s stock valued at $114,000 after buying an additional 11,175 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Zacks Research lowered shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 20th. TD Cowen restated a “buy” rating on shares of NeoGenomics in a research report on Monday, March 16th. Benchmark reaffirmed a “hold” rating on shares of NeoGenomics in a report on Wednesday, February 18th. Needham & Company LLC lifted their price target on NeoGenomics from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Finally, UBS Group reiterated a “hold” rating on shares of NeoGenomics in a research note on Wednesday, February 18th. Five analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $11.86.

NeoGenomics Price Performance

Shares of NASDAQ:NEO opened at $7.19 on Friday. The company has a 50 day moving average of $10.24 and a 200 day moving average of $10.46. The company has a current ratio of 4.26, a quick ratio of 3.94 and a debt-to-equity ratio of 0.41. The stock has a market cap of $933.33 million, a P/E ratio of -8.56 and a beta of 1.62. NeoGenomics, Inc. has a 12 month low of $4.72 and a 12 month high of $13.74.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, February 17th. The medical research company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. NeoGenomics had a negative net margin of 14.85% and a negative return on equity of 3.10%. The business had revenue of $190.17 million for the quarter, compared to analysts’ expectations of $188.25 million. During the same period in the prior year, the company posted $0.04 EPS. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. As a group, sell-side analysts forecast that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

Insider Activity

In related news, COO Warren Stone sold 22,128 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $12.50, for a total value of $276,600.00. Following the sale, the chief operating officer owned 121,631 shares in the company, valued at approximately $1,520,387.50. This trade represents a 15.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 2.40% of the company’s stock.

NeoGenomics Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.